Fennec Pharmaceuticals (FENC) Non-Current Receivables (2025)
Fennec Pharmaceuticals posted quarterly Non-Current Receivables of $2.8 million for Q4 2025, up 13.73% on a QoQ basis from $2.5 million in Q3 2025.
Fennec Pharmaceuticals (FENC) has 1 years of Non-Current Receivables data on file, last reported at $2.8 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Receivables changed N/A year-over-year to $2.8 million; the trailing twelve-month figure through Dec 2025 stood at $2.8 million (changed N/A YoY), and the FY2025 full-year result was $2.8 million, changed N/A from the prior year.
- Non-Current Receivables for Q4 2025 stood at $2.8 million, up from $2.5 million in the prior quarter.
- Across five years, Non-Current Receivables topped out at $3.3 million in Q2 2025 and bottomed at $2.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.49 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Fennec Pharmaceuticals | 281.48 Mn | 244.70 Mn | 7.67 Mn | 2.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.79 Mn |
| Sep 30, 2025 | 2.45 Mn |
| Jun 30, 2025 | 3.31 Mn |
| Mar 31, 2025 | 2.63 Mn |